Overview
Local News
2010-07-08
Bayer Animal Health and ParaCo agree on access to lead molecules
Monheim (GER) /Hamilton (NZ), July 8, 2010 – Bayer Animal Health GmbH and ParaCo Technologies Limited, a 100% owned subsidiary of AgResearch, New Zealand’s largest Crown Research Institute, today announced they have signed an option agreement allowing Bayer exclusive access to ParaCo’s current lead molecules for testing and development in animal health. The focus in the foreseen activities lies in the research of parasiticides. » more
Monheim (GER) /Hamilton (NZ), July 8, 2010 – Bayer Animal Health GmbH and ParaCo Technologies Limited, a 100% owned subsidiary of AgResearch, New Zealand’s largest Crown Research Institute, today announced they have signed an option agreement allowing Bayer exclusive access to ParaCo’s current lead molecules for testing and development in animal health. The focus in the foreseen activities lies in the research of parasiticides. » more
2010-05-31
Judges ready to be impressed at Bayer Innovations Awards
Auckland - Bayer, a global leader in innovation, is pleased to announce the judges for the upcoming Bayer Innovators Awards 2010. Dr Steve Henry, Rick Christie and Professor Jacqueline Rowarth will preside over the search for New Zealand’s top innovators. » more
Auckland - Bayer, a global leader in innovation, is pleased to announce the judges for the upcoming Bayer Innovators Awards 2010. Dr Steve Henry, Rick Christie and Professor Jacqueline Rowarth will preside over the search for New Zealand’s top innovators. » more
2010-05-03
Search begins for New Zealand’s leading innovators
Bayer, a global leader in innovation, is looking for New Zealand’s most innovative people to enter the Bayer Innovators Awards, in association with the National Business Review.» more
Bayer, a global leader in innovation, is looking for New Zealand’s most innovative people to enter the Bayer Innovators Awards, in association with the National Business Review.» more
Bayer Global News
2010-06-17
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway
Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway
Bayer Global News Overview
Bookmark this page
E-mail this page
